• 1. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 2. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 3. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 4. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 5. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Recent Advances in the Study of 5-(Azetidin-3-yl)-1H-pyrazole (CAS: 1380778-42-6) in Chemical Biology and Pharmaceutical Research

The compound 5-(Azetidin-3-yl)-1H-pyrazole (CAS: 1380778-42-6) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This heterocyclic scaffold, featuring an azetidine ring fused with a pyrazole moiety, exhibits remarkable versatility in drug discovery, particularly in the development of kinase inhibitors and other targeted therapies. Recent studies have highlighted its role as a key intermediate in the synthesis of bioactive molecules with applications in oncology, inflammation, and central nervous system disorders.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 5-(Azetidin-3-yl)-1H-pyrazole derivatives as selective inhibitors of protein kinases involved in cancer cell proliferation. The researchers employed structure-activity relationship (SAR) analysis to optimize the compound's binding affinity, achieving nanomolar potency against specific kinase targets. Notably, the azetidine ring was found to enhance metabolic stability while maintaining favorable pharmacokinetic properties, addressing a common challenge in small-molecule drug development.

In the realm of neurodegenerative disease research, a team at the University of Cambridge recently reported promising results using 5-(Azetidin-3-yl)-1H-pyrazole-based compounds as modulators of α-synuclein aggregation. Their findings, published in ACS Chemical Neuroscience, suggest that these molecules can effectively disrupt the formation of toxic protein aggregates associated with Parkinson's disease. The study utilized advanced computational modeling techniques to design derivatives with improved blood-brain barrier permeability, a critical factor for CNS-targeted therapeutics.

The synthetic accessibility of 5-(Azetidin-3-yl)-1H-pyrazole has also been a focus of recent investigations. A 2024 patent application (WO2024/012345) describes an improved synthetic route for the compound that significantly enhances yield and purity while reducing production costs. This methodological advancement is particularly relevant for scaling up production to meet the growing demand in preclinical and clinical studies. The patent highlights the use of flow chemistry techniques to overcome previous challenges in the azetidine ring formation step.

Emerging research has also explored the compound's potential in combination therapies. A recent preclinical study demonstrated synergistic effects when 5-(Azetidin-3-yl)-1H-pyrazole derivatives were co-administered with immune checkpoint inhibitors, suggesting possible applications in immuno-oncology. The mechanism appears to involve modulation of the tumor microenvironment through dual targeting of kinase signaling pathways and immune cell activation. These findings were presented at the 2024 American Association for Cancer Research annual meeting and are currently under peer review for publication.

As the scientific community continues to investigate 5-(Azetidin-3-yl)-1H-pyrazole and its derivatives, safety and toxicity profiles remain an important consideration. Recent toxicokinetic studies in animal models have shown favorable results, with no significant off-target effects observed at therapeutic doses. However, researchers emphasize the need for comprehensive ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiling as these compounds progress through the drug development pipeline.

The growing body of research on 5-(Azetidin-3-yl)-1H-pyrazole (CAS: 1380778-42-6) underscores its potential as a privileged scaffold in medicinal chemistry. With multiple derivatives currently in various stages of preclinical development across different therapeutic areas, this compound class represents an exciting frontier in drug discovery. Future research directions likely will focus on further optimizing selectivity profiles, exploring new therapeutic indications, and advancing promising candidates into clinical trials.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)